SCHEMBL15044974

SCHEMBL15044974

CC(C)c1ncc(-c2cnn(C)c2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR55 Q9Y2T6 1/20 0.43
ALOX5AP P20292 4/20 0.40
CHEK1 O14757 1/20 0.40
CHEK2 O96017 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
LRRK2 Q5S007 2/20 0.39
MAPT P10636 1/20 0.38
MET P08581 3/20 0.38
MST1R Q04912 1/20 0.38
AURKA O14965 1/20 0.38
TTK P33981 1/20 0.38
AURKB Q96GD4 1/20 0.38
INCENP Q9NQS7 1/20 0.38
IRAK1 P51617 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
ERN1 O75460 1/20 0.37
ACVR1 Q04771 1/20 0.37
PDK2 Q15119 1/20 0.37
MAPK1 P28482 1/20 0.36
PIM1 P11309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13807047 0.78 LRRK2 (0.45) GPR55CHEK1CHEK2LRRK2MAPT
SCHEMBL20437895 0.77 GPR55 (0.50) GPR55ALOX5APLRRK2MAPTIRAK1
SCHEMBL24198392 0.76 RET (0.36) GPR55KDM5BLRRK2AURKATTK
SCHEMBL2220124 0.76 AXL (0.46) GPR55CHEK1CHEK2LRRK2MAPT
SCHEMBL20150132 0.76 ALOX5AP (0.50) ALOX5APCHEK1CHEK2LRRK2MET
SCHEMBL26953500 0.76 CHEK1 (0.42) GPR55ALOX5APCHEK1CHEK2LRRK2
SCHEMBL12919977 0.73 GPR55 (0.50) GPR55ALOX5APLRRK2AURKBACVR1
SCHEMBL22663603 0.73 KDM5B (0.43) GPR55ALOX5APCHEK1CHEK2KDM5B
SCHEMBL24921579 0.73 CHEK1 (0.47) GPR55CHEK1CHEK2LRRK2MAPT
SCHEMBL18927534 0.73 CHEK1 (0.40) GPR55CHEK1CHEK2LRRK2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374008-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-11-23 US disclosed
US-20210371375-A1 hTERT MODULATORS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-12-02 US disclosed
US-10556860-B2 hTERT modulators and methods of use ARIZONA BOARD OF REGENTS (US) 2020-02-11 US disclosed
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GPR39 GPR55 14/4885ALOX5AP 2439/4885CHEK1 4464/4885
US-10556860-B2 hTERT modulators and methods of use TERT, POT1, TERF2 GPR55 2145/4885ALOX5AP 3205/4885CHEK1 980/4885
US-20230374008-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 GPR55 3687/4885ALOX5AP 3394/4885CHEK1 4635/4885
US-20210371375-A1 hTERT MODULATORS AND METHODS OF USE TERT, TERF2, RB1 GPR55 2199/4885ALOX5AP 3709/4885CHEK1 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.